Melbourne, Australia – 18 January 2023: Adherium Limited...

Melbourne, Australia – 18 January 2023:
Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce a £499,871 (approximately $880,000) award for a pathfinder service development project from the UK National Health Service’s Small Business Research Initiative Healthcare1 (SBRI Healthcare).

The project is titled “Smart Digital inhaler enabled asthma management in high-risk children aged 5 to 16 years managed in primary care to prevent asthma attacks.”

Children with asthma often have flare-ups that require hospitalisation. This project will use Hailie® digital inhalers that alert the child and display usage on the family’s smartphone. Via the web, the medical team can monitor and support families and their child’s medication; with the aim to reduce these asthma attacks.

“This is a unique opportunity and privilege to reach high risk children early and potentially save them and their families from the repeated challenge of exacerbations. These cause distress and can lead to emergency department visits and hospitalisation” says Francis White, Adherium’s VP of Global Business Development.

This project, to be completed by December 2023, deploys Adherium’s clinically proven Hailie® Digital Inhaler Solution to a real-world setting, offering early intervention and monitoring to children that fulfil the criteria of a high-risk, high-likelihood of exacerbations. Adherium’s partner, Helicon Health Ltd, will be working with the research team led by Dr Erol Gaillard at the University of Leicester, to identify patients in primary care and offer them the Hailie system.

The project is also backed by the Leicester Integrated Care Board, East Midlands AHSN.

Adherium Limited (ACN 605 352 510) Collins Square, Tower 4, Level 18, 727 Collins Street Melbourne VIC 3000 Australia www.adherium.com | www.hailie.com | [email protected] More information and updates will follow as the project progresses. Summary information about the pathfinder service development project is outlined here: https://sbrihealthcare.co.uk/news/t...7-million-to-respiratory-disease-innovations/ 1. SBRI Healthcare is a National Health Service (NHS) England & NHS Improvement initiative, supported by the Academic Health Science Network (AHSN) and managed by LGC Group. It aims to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice.

The award is to Adherium Europe Ltd, a wholly owned subsidiary of Adherium Ltd. -ENDSAbout Adherium (ASX: ADR) Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

..................

Recognition is getting out there globally, which is great... however from a shareholders perspective, taking into consideration the cash burn etc, I believe Adherium need to step up the pace... its somewhat frustrating getting this announcements but with no actual serious meat in them to show strong streams of revenue from our sensors... I feel like theres no urgency happening here.. fat incomes, typical small cap that is recently again cashed up... the trading here annoys me... about time we saw some serious churn in shares and got of this hell bottom that we seem to be stuck on at .004-.005... who keeps dumping and selling at these levels... to be selling at .004 is nothing more than a huge loss for many... considering the massive raise at .005 who keeps dumping at .004.... that wall at .005 is also annoying as hell...it would seem Adherium has massive potential, but do we have the right leaders in place here... will we ever see some serious revenue in the short term???????... frustrating isnt it...